Fig. 4.

Macrophages primed by resolution type secretome exposure modulate the expression of CXCR3 on Th1 cells. a Experimental scheme of the transfer of CFSE-labeled spleen cells from EAE mice treated or not by SuperMApo. b Percentages of CFSE positive cells from different origin (EAE + vehicle or EAE + SuperMApo mice) in the spleen, inguinal lymph node (iLN) and spinal cord (SC). Data pooled from 2 independent experiments. c Percentage of CFSE positive B, T and dendritic cells (DC) in the spleen and iLN of mice as in b. Data pooled from 2 independent experiments shown as mean ± SEM. d Expression of Cxcr3, Ccr5 and Ccr6 mRNA in the spleen and iLN cells issued from vehicle- (EAE) or SuperMApo-treated mice (+ SuperMApo). Data from a representative experiment out of 3 showing similar results, shown as mean ± SEM, 4 mice per group. e Expression of CXCR3 on Th1, Th17, Tc1, DC and macrophages in the spleen of mice as in d. Data from a representative experiment out of 3 showing similar results, shown as mean ± SEM, 5 mice per group. f Expression of CXCR3 in Th1 cells after co-culture of naive CD25^‒CD4⁺ T cells with macrophages pretreated by SuperMApo or control medium, depicted as representative histograms (left) or cumulated including mean ± SEM (right). Data from a representative experiment out of 3 showing similar results. g Expression of CXCR3 on spleen Th1 cells from EAE mice depleted for phagocytes (EAE + Clodro-lipo) treated or not with SuperMApo (+ SMA). Data pooled from two independent experiments shown as mean ± SEM from 4 to 5 mice per group. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, unpaired two-tailed Student’s t test